"
Team:SupBiotech-Paris/Acknowledgement
From 2009.igem.org
(Difference between revisions)
Enguerrand (Talk | contribs) (→Our Sponsors) |
Enguerrand (Talk | contribs) |
||
| Line 2: | Line 2: | ||
{{Template:SupbiotechparisEn}} | {{Template:SupbiotechparisEn}} | ||
| - | + | == Our scientific == | |
| - | + | ||
| - | + | === UMR CNRS 8121 from the Gustave Roussy Institute === | |
| - | + | ||
| - | ==UMR CNRS 8121 from the Gustave Roussy Institute== | + | |
:* Dr. Lluis M. Mir | :* Dr. Lluis M. Mir | ||
:* Dr. Karim Benihoud | :* Dr. Karim Benihoud | ||
| - | ==INSERM U872== | + | === INSERM U872 === |
:* Dr. Srinivas Kaveri | :* Dr. Srinivas Kaveri | ||
| - | ==AnyGenes== | + | === AnyGenes === |
:* Dr. Benyoussef Naimi | :* Dr. Benyoussef Naimi | ||
| - | ==National Reference Center for Mycobacteria and the Resistance of Mycobacteria to Antituberculosis from CHU Pitié-Salpêtrière== | + | === National Reference Center for Mycobacteria and the Resistance of Mycobacteria to Antituberculosis from CHU Pitié-Salpêtrière === |
:* Dr. Nicolas Veziris | :* Dr. Nicolas Veziris | ||
Revision as of 15:48, 29 September 2009
Project
Introduction Current therapies Gene therapies DVS Concept Tissue Vector Cell Vector Therapeutic plasmid Conclusion Implementation Tissue targeting Antitumor action Treatment modeling Conclusion
Ressources
BioBricks Material & Method Bibliography
Ethics & Safety
Contents |
Our scientific
UMR CNRS 8121 from the Gustave Roussy Institute
- Dr. Lluis M. Mir
- Dr. Karim Benihoud
INSERM U872
- Dr. Srinivas Kaveri
AnyGenes
- Dr. Benyoussef Naimi
National Reference Center for Mycobacteria and the Resistance of Mycobacteria to Antituberculosis from CHU Pitié-Salpêtrière
- Dr. Nicolas Veziris
Our Sponsors
